The share price of Open Orphan (LON: ORPH) continued its rapid surge on Friday after the pharmaceutical company issued a brief update on the proposed COVID-19 vaccine challenger trials.
With shares in ORPH nearly doubling in the past month to 28p, the company has rewarded investors with a 460% return in the year-to-date.
On Friday, ORPH shares gained nearly 7 percent after it confirmed advanced talks with the UK government over COVID-19 vaccine challenge trials:
“Further to our announcement of 24 September 2020 and further media comment the Company confirms that it remains in advanced negotiations with the UK Government and other partners for a Coronavirus challenge study in the UK. No contract has been signed and the Company will update the market in due course as appropriate.”
Any proposed human challenge trials would have to be approved by the Medicines and Healthcare products Regulatory Agency.